Bay­er's new busi­ness unit teams up with Ma­hana Ther­a­peu­tics to com­mer­cial­ize dig­i­tal treat­ments

Bay­er is team­ing up with Ma­hana Ther­a­peu­tics in a “mul­ti-mil­lion-dol­lar” dis­tri­b­u­tion and mar­ket­ing part­ner­ship to com­mer­cial­ize dig­i­tal ther­a­peu­tics, Ma­hana an­nounced to­day.

De­tails in the state­ment from Ma­hana are sparse, and both com­pa­nies de­clined to re­veal more de­tails about the dol­lar amount of the part­ner­ship.

Ma­hana CEO Si­mon Levy said in a state­ment the deal is “among the first ma­jor in­vest­ments ever made by a glob­al life sci­ences com­pa­ny in­to the emerg­ing mar­ket­place for dig­i­tal ther­a­peu­tics” and that the part­ner­ship is with Bay­er’s con­sumer health di­vi­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER